Miren Taberna

Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis

Hisham Mehanna, Miren Taberna, Christian von Buchwald et al. · The Lancet Oncology · 2023 · 281 citations · Full text

Medicine, Oncology, Molecular Oncology +9

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 232 citations

Medicine, Oncology, Chemotherapy +14

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra et al. · The Lancet Oncology · 2024 · 210 citations · Full text

Medicine, Oncology, Pharmacology +16

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651

Robert I. Haddad, Kevin J. Harrington, Makoto Tahara et al. · Journal of Clinical Oncology · 2022 · 158 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

SEOM clinical guidelines for the treatment of head and neck cancer (2020)

L. Iglesias, J. Lambea, Javier Martínez‐Trufero et al. · Clinical & Translational Oncology · 2021 · 103 citations · Full text

Medicine, Oncology, Surgery +17